Profile data is unavailable for this security.
About the company
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
- Revenue in CAD (TTM)0.00
- Net income in CAD-13.82m
- Incorporated2015
- Employees18.00
- LocationMedicenna Therapeutics Corp2 Bloor St W., 7Th FloorTORONTO M4W 3E2CanadaCAN
- Phone+1 (416) 648-5555
- Fax+1 (416) 648-5555
- Websitehttps://www.medicenna.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MustGrow Biologics Corp | 7.54m | -6.37m | 40.23m | 0.00 | -- | 12.95 | -- | 5.34 | -0.1206 | -0.1206 | 0.1435 | 0.0494 | 1.45 | 5.49 | 45.16 | -- | -122.84 | -54.87 | -193.93 | -66.95 | 14.51 | -- | -84.52 | -341.26 | 1.25 | -103.31 | 0.1671 | -- | -91.55 | -- | -622.18 | -- | -- | -- |
| Briacell Therapeutics Corp | 0.00 | -38.90m | 41.61m | 22.00 | -- | 0.7996 | -- | -- | -72.20 | -72.20 | 0.00 | 7.18 | 0.00 | -- | -- | 0.00 | -246.96 | -63.88 | -359.42 | -70.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -449.14 | -- | -- | -- |
| ZYUS Life Sciences Corp | 465.00k | -33.74m | 48.36m | 2.00 | -- | -- | -- | 104.01 | -0.4505 | -0.4505 | 0.0062 | -0.1659 | 0.0208 | 0.3346 | 1.17 | -- | -150.55 | -74.90 | -454.68 | -102.81 | 13.12 | 3.61 | -7,256.77 | -8,974.20 | 0.0726 | -9.28 | 6.94 | -- | 37.04 | 313.06 | 20.63 | -- | -- | -- |
| Nurexone Biologic Inc | 0.00 | -8.85m | 58.02m | 9.00 | -- | 26.72 | -- | -- | -0.1189 | -0.1189 | 0.00 | 0.0239 | 0.00 | -- | -- | -- | -208.79 | -215.30 | -263.35 | -529.63 | -- | -- | -- | -- | -- | -102.73 | 0.0514 | -- | -- | -- | -38.58 | -- | -- | -- |
| Medicenna Therapeutics Corp | 0.00 | -13.82m | 65.89m | 18.00 | -- | 6.43 | -- | -- | -0.1696 | -0.1696 | 0.00 | 0.1228 | 0.00 | -- | -- | 0.00 | -54.21 | -56.44 | -63.31 | -63.20 | -- | -- | -- | -- | -- | -- | 0.0143 | -- | -- | -- | 53.64 | -- | -- | -- |
| Sharp Therapeutics Corp | 0.00 | -9.19m | 66.01m | -- | -- | 34.40 | -- | -- | -4.11 | -4.11 | 0.00 | 0.0639 | 0.00 | -- | -- | -- | -435.86 | -- | -512.62 | -- | -- | -- | -- | -- | -- | -- | 0.477 | -- | -- | -- | -2,282.81 | -- | -- | -- |
| Zentek Ltd | 915.32k | -8.19m | 94.62m | 17.00 | -- | 7.89 | -- | 103.37 | -0.0785 | -0.0785 | 0.0088 | 0.1115 | 0.048 | 0.4823 | 5.22 | 53,842.35 | -42.98 | -56.35 | -50.88 | -61.72 | 48.68 | -83.98 | -895.31 | -5,414.02 | 0.5344 | -- | 0.1391 | -- | 2,825.89 | -- | 14.22 | -- | -35.15 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Oct 2025 | 5.27m | 7.67% |
| AIGH Capital Management LLCas of 30 Jun 2025 | 4.67m | 6.80% |
| Next Edge Capital Corp.as of 30 Jun 2024 | 0.00 | 0.00% |
